SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
AbbVie_© AbbVie Inc. All rights reserved.
Drug Development
AbbVie Enjoys Strong Second Quarter as Rinvoq Gears Up to Succeed Humira
The company saw global net revenue of $13.9 billion during the second quarter, an increase of 33.9%. Sales were primarily driven by its immunology portfolio, which generated $6.12 billion.
August 2, 2021
 · 
3 min read
 · 
Alex Keown
Business
AbbVie/Calico Innovation Engine Will Keep On Chugging Against Age-Related Diseases
The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.
July 28, 2021
 · 
2 min read
 · 
Heather McKenzie
Michael Vi/Shutterstock
Deals
$2.5B Teneobio Deal Complements Amgen’s Core and Capabilities
Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.
July 28, 2021
 · 
3 min read
 · 
Alex Keown
Allergan eye drops are showing promising results i
Drug Development
Allergan Eye Drops for Presbyopia Hits All Endpoints, Focuses In on Approval
The company said its Allergan eye drops met both its primary and key secondary endpoints, with patients reporting near and intermediate improvements in vision.
July 26, 2021
 · 
3 min read
 · 
Vanessa Doctor, RN
Job Trends
The BioMidwest Region Features Lifestyle Bonuses and Cutting-Edge Science
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
July 26, 2021
 · 
4 min read
 · 
Heather McKenzie
Courtesy of Smith Collection/Gado/Getty Images
FDA
FDA Greenlights AbbVie’s Antibiotic Dalvance for Acute Skin Infections in Children
The U.S. Food and Drug Administration (FDA) approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients as young as newborns.
July 23, 2021
 · 
3 min read
 · 
Mark Terry
Pharm Country
BioSpace’s Business Report Highlights Sustained Growth and New Blood
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
July 22, 2021
 · 
5 min read
 · 
Heather McKenzie
Michael Vi/Shutterstock
Drug Development
Genentech’s Combo Therapy for Rare Blood Cancers Scores Breakthrough Designation
Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.
July 21, 2021
 · 
2 min read
 · 
Vanessa Doctor, RN
Job Trends
Frontier Medicines Raises $88.5 Million to Advance Chemoproteomics Program
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
July 19, 2021
 · 
3 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
FDA
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
April 29, 2022
 · 
21 min read
Business
AbbVie Reports First-Quarter 2022 Financial Results
April 29, 2022
 · 
24 min read
Business
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
April 28, 2022
 · 
4 min read
Business
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
April 20, 2022
 · 
2 min read
Business
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
April 20, 2022
 · 
3 min read
Job Trends
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 19, 2022
 · 
9 min read
Business
AbbVie to Host First-Quarter 2022 Earnings Conference Call
April 14, 2022
 · 
1 min read
Drug Development
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
April 13, 2022
 · 
10 min read
Job Trends
AbbVie Celebrates 30th Anniversary of CF Scholarship with Opening of Application Period for Students with Cystic Fibrosis
April 13, 2022
 · 
4 min read
FDA
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
April 13, 2022
 · 
8 min read
Load More